Daiichi Sankyo Clinical Trial Pipeline — 60 Active Studies

Phases, active trials: Phase 1: 16, Phase 2: 15, Phase 3: 22, Other: 7

Daiichi Sankyo has emerged as the global leader in antibody-drug conjugate (ADC) oncology through its proprietary DXd payload technology platform. Their collaboration with AstraZeneca on three blockbuster ADCs — Enhertu (trastuzumab deruxtecan, HER2), Dato-DXd (datopotamab deruxtecan, TROP2), and patritumab deruxtecan (HER3) — has reshaped the competitive landscape in breast cancer, NSCLC, and gastric cancer. Enhertu's DESTINY-Breast and DESTINY-Gastric trials have set new benchmarks for HER2-low breast cancer and HER2-positive gastric cancer, expanding the HER2 targetable population. Daiichi Sankyo's wholly-owned pipeline includes ifinatamab deruxtecan (IFD, targeting B7-H3) for small cell lung cancer and other solid tumors, raludotatug deruxtecan (R-DXd, targeting CDH6) for ovarian and kidney cancers, and multiple DXd ADC combinations across indications.

• Breast cancer (HER2, HER2-low, TROP2, HER3)
• Non-small cell lung cancer (HER2, HER3, TROP2)
• Gastric / gastroesophageal cancer (HER2)
• Small cell lung cancer (B7-H3)
• Ovarian / renal cancer (CDH6)

• Enhertu (trastuzumab deruxtecan) — HER2-targeting DXd ADC
• Dato-DXd (datopotamab deruxtecan) — TROP2 DXd ADC
• Patritumab deruxtecan (HER3-DXd) — HER3 DXd ADC
• Ifinatamab deruxtecan (I-DXd) — B7-H3 DXd ADC, SCLC
• Raludotatug deruxtecan (R-DXd) — CDH6 DXd ADC, ovarian/renal
• DS-6000 — CDH6-targeting DXd ADC

Daiichi Sankyo registers ADC expansion trials across multiple tumor types continuously — every new Enhertu, Dato-DXd, or patritumab deruxtecan trial represents competitive intelligence for companies in breast cancer, NSCLC, and gastric cancer. Their pipeline of next-generation DXd ADCs (IFD for SCLC, R-DXd for ovarian) is closely watched for B7-H3 and CDH6 targeting precedent.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Daiichi Sankyo's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Daiichi Sankyo may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.